Delivra Health (DHBUF) Stock News

Delivra Health (OTCQB: DHBUF) is launching Dream Water Kids Sleep Gummies in the U.S., expected to reach distributors, retailers and e-commerce channels in June 2026. The gummies contain chamomile, lemon balm and 1 mg melatonin, are gelatin- and gluten-free, and use honey and cane sugar.

The company also granted 815,000 incentive stock options at $0.16 per share, five-year term, vesting one-third annually.

Delivra Health (OTCQB: DHBUF) reported Q2 fiscal 2026 results for the three and six months ended December 31, 2025. Total net revenue was $2.43M in Q2 (down 12% YoY) and $5.64M year-to-date (down 5% YoY). E-commerce sales grew: Dream Water +26% and LivRelief +28% YTD. Gross profit fell to $972k (40% margin) in Q2 and $2.47M (44% margin) YTD, pressured by product cost increases and customer mix. Adjusted EBITDA was negative $369k in Q2 and negative $313k YTD. Management cites retail timing and distribution transitions as temporary, targeting channel optimization in H2 2026.

Delivra Health Brands (OTCQB: DHBUF; TSXV: DHB) announced the appointment of John Barrett as a director and the resignation of Andrew Bayfield, effective January 30, 2026. Mr. Barrett brings North American and international consumer goods expertise and oversight of over $1 billion in profit and loss.

The appointment is subject to approval by the TSX Venture Exchange. Management says Barrett's commercial and go-to-market experience will support the company's next growth stage and strategic priorities.

Delivra Health (OTCQB: DHBUF) reported Q1 2026 results for the three months ended September 30, 2025, with net revenue of $3.207M versus $3.163M a year earlier and gross profit of $1.501M (47% margin). The company highlighted brand growth: Dream Water e-commerce +74% YoY and Dream Water US/Canada +8% YoY; LivRelief e-commerce +16% YoY.

Adjusted EBITDA improved to $56k from $16k a year earlier; net loss narrowed to $91k from $478k. Licensed LivRelief Infused sales fell 89% ($195k) during a distributor transition; a relaunch is planned for January 2026.

Delivra Health Brands (OTCQB: DHBUF) reported fiscal 2025 results for the 12 months ended June 30, 2025, showing net revenue of $13,370k, up 8% year-over-year from $12,378k. Gross profit rose to $6,778k with a 51% gross margin (vs. 52% in 2024). Adjusted EBITDA was $643k, down from $871k in fiscal 2024, reflecting higher marketing and e-commerce costs.

Brand performance: Dream Water USA & Canada and LivRelief Canada delivered double-digit revenue growth in e-commerce and retail channels, partially offset by lower licensed LivRelief Infused revenues. Fiscal 2025 showed a net loss from continuing operations of $1,190k and operating cash use of $754k.

Delivra Health (OTCQB: DHBUF; TSXV: DHB) will report annual financial results for the year ending June 30, 2025 on Monday, October 6, 2025. The company will host a conference call on Monday, October 6, 2024 at 11:00 a.m. EST / 8:00 a.m. PST featuring CEO Gord Davey and CFO Jack Tasse, followed by a Q&A. Participants may dial 1-833-752-2525 (Canada/USA toll free) or +1-647-846-2674 (international). A replay will be posted on the company's investor page by end of business on October 6, 2025.

Delivra Health Brands (OTCQB: DHBUF) has announced the expansion of its Dream Water brand into the Gulf Cooperation Council (GCC) market with the launch of 6-Count Sleep Gummies. The new product will be available in airports, major pharmacies, and e-commerce channels by September 2025, focusing on Saudi Arabia and other GCC countries.

The company, through its distribution partners in Saudi Arabia, aims to capitalize on the high-growth market for wellness and sleep-support products in the Middle East. Additionally, Delivra Health has granted 100,000 incentive stock options to certain directors, officers, and employees, exercisable at $0.30 per share with a three-year term.

Delivra Health Brands (TSXV: DHB) (OTCQB: DHBUF) has expanded its US presence through a new partnership with QVC, a major televised and online shopping network. The partnership enables Dream Water's Snoozeberry Sleep Shots to reach millions of potential customers through QVC's direct-to-consumer platform. The initial product launch features a 16-pack of Dream Water Snoozeberry Sleep Shots, which first aired on May 31, 2025, and will continue to be available on QVC's website. CEO Gord Davey emphasized that this partnership aligns with the company's strategy to expand distribution channels and leverage QVC's engaging hosts and storytelling approach to build brand loyalty and drive impulse purchases.

Delivra Health Brands (DHBUF) reported its Q3 2025 financial results, showing positive growth and strategic expansion. The company achieved a 3% year-over-year revenue increase to $9,012,000 for the nine months ended March 31, 2025, with positive adjusted EBITDA of $124,000 in Q3. Dream Water brand expanded in Canada with new product launches including Sleep Shot extensions and Sleep Gummies. LivRelief's "Quiets Chronic Pain" campaign drove a 21% increase in units sold to 95,000 units. However, gross profit margin declined to 49% from 52% due to higher costs and product mix changes. The company's strategic marketing investments led to a 15% increase in expenses to $4,585,000, impacting the nine-month adjusted EBITDA which decreased to $(51,000) from $845,000 in the previous year.